NCT00332657

Anecortave Acetate Risk Reduction Trial (AART)

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Alcon Research · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to demonstrate that Anecortave Acetate for Depot Suspension (15 mg or 30 mg) is safe and effective in arresting the progression of dry age-related macular degeneration (AMD) in patients who are at-risk for progressing to wet AMD.

Conditions

• AMD

Interventions

Type	Name	Description
DRUG	Anecortave Acetate Sterile Suspension, 30 mg/mL	One 0.5 mL injection into the PJD at 6-month intervals for 42 months
DRUG	Anecortave Acetate Sterile Suspension, 60 mg/mL	One 0.5 mL injection into the PJD at 6-month intervals for 42 months
OTHER	Anecortave Acetate Vehicle	One 0.5 mL sham injection at 6-month intervals for 42 months. Syringe and vehicle were not inserted into the eye.

Timeline

• Start date: 2006-09-01
• Primary completion: 2008-12-01
• Completion: 2008-12-01
• First posted: 2006-06-02
• Last updated: 2012-11-28

Locations

1 site across 1 country: India